Electroacupuncture to relieve diarrhea after chemotherapy:a randomized controlled trial

anjing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. The selected cases must meet the tumor diagnosis criteria of the China Common Malignant Tumor Diagnosis and Treatment Standards of the Health Commission of the People's Republic of China, and are confirmed to be malignant by histopathology and/or cytology;
•2. Those who are prepared to receive or are receiving platinum, paclitaxel, or vincristine drugs as planned, and have diarrhea after chemotherapy;
•3. Between 18-75 years old;
•4. ECOG <= 3 points; the expected survival period of subjects >= 6 months;
•5. No serious heart, liver, lung, or kidney organic disease;
•6. Voluntary signing of informed consent to join the researcher.

•1. Patients with upper respiratory tract infection and other symptoms of infection at the time of consultation;
•2. Those who have recently used antibiotics and other drugs that may cause diarrhea;
•3. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period;
•4. Patients with clinically significant ECG abnormalities;
•5. People with pacemakers;
•6. Participate in other clinical trials within 30 days;
•7. Those with gastrointestinal tumors that may affect bowel function as judged by a specialist;
•8. Those with functional bowel disease or intestinal infectious disease;
•9. Colostomy;
•10. People who use opioid analgesics;
•11. People with severe intestinal obstruction and incomplete intestinal obstruction;
•12. People with severe coagulopathy and bleeding tendency;
•13. People with a tendency to severe gastrointestinal perforation;
•14. People with mental illness;
•15. Less than 4 weeks since the last chemotherapy;
•16. Lactose intolerant;
•17. Patients with celiac disease;
•18. Patients with type 1 diabetes or uncontrolled type 2 diabetes.

发起方

anjing University of Chinese Medicine